AZD4512

DRUG3 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

B-cell Non-Hodgkin LymphomaB-cell acute lymphoblastic leukemia (B-ALL)Non-Hodgkin lymphoma (NHL)

Phase 1

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

RecruitingNCT07123454

AstraZenecaB-cell Non-Hodgkin Lymphoma

Start: 2025-09-24End: 2028-03-01Target: 91Updated: 2026-08-28

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

RecruitingCTIS2025-522371-29-00

AstraZeneca ABNon-Hodgkin lymphoma (NHL)

Start: 2025-12-19Target: 12Updated: 2025-11-18

A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia

RecruitingCTIS2025-522372-93-00

AstraZeneca ABB-cell acute lymphoblastic leukemia (B-ALL)

Start: 2026-01-13Target: 13Updated: 2026-01-23